10-Q: Skye Bioscience Q1 2026: Nimacimab Trial Data, Nasdaq Compliance Concerns

Skye Bioscience reports Q1 2026 financial results, detailing progress and challenges in nimacimab development, alongside Nasdaq listing concerns and ongoing litigation.

Summary

• Skye Bioscience reported a net loss of $12,509,361 for the three months ended March 31, 2026, compared to a net loss of $11,103,319 for the same period in 2025.
• Research and development expenses increased by 10% to $7,935,680 in Q1 2026, primarily due to clinical trial and manufacturing costs for nimacimab.
• General and administrative expenses saw a modest increase of 4% to $4,738,686 in Q1 2026, influenced by increased legal fees.
• The company has sufficient capital to fund operations through Q4 2026, but requires additional funding for a proposed Phase 2b study and manufacturing.
• Skye Bioscience received a deficiency notice from Nasdaq on March 17, 2026, for failing to maintain a minimum closing bid price of $1.00 per share, with a compliance deadline of September 14, 2026.
• The company is involved in ongoing litigation, including the Wendy Cunning lawsuit, with a new trial scheduled for May 2026, and a securities class action and derivative lawsuits filed in late 2025 and early 2026.
• Topline results from the nimacimab Phase 2a extension study showed continued weight loss in combination therapy, with a mean weight loss of 22.3% after 52 weeks in one cohort.
• An expansion study assessing intravenous administration of nimacimab is underway, with topline data expected in Q4 2026.
• The company is evaluating data to inform the design of a potential Phase 2b study for nimacimab as a combination therapy.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the failure of nimacimab monotherapy to meet its primary endpoint, ongoing Nasdaq compliance issues, and substantial doubt about the company's ability to continue as a going concern, despite positive combination therapy data.

Positives

• Nimacimab in combination with semaglutide demonstrated a clinically meaningful magnitude of weight loss (-13.2% vs. -10.25% for semaglutide alone) in the Phase 2a study.
• In the combination arm, 100% of patients achieved greater than 5% weight loss and 67% achieved greater than 10% weight loss.
• Nimacimab plus semaglutide showed a significant improvement in waist circumference compared to semaglutide alone.
• An improvement in lean mass to fat mass ratio was observed in the nimacimab plus semaglutide combination arm compared to semaglutide alone.
• The nimacimab plus semaglutide combination arm showed a decrease in rebound weight gain post-treatment compared to semaglutide alone.
• Interim results from the Phase 2a extension study showed continued weight loss in the nimacimab plus semaglutide combination cohort, reaching a mean weight loss of 22.3% after 52 weeks.
• Nimacimab demonstrated a favorable safety profile with placebo-like tolerability, and no increase in neuropsychiatric adverse events.
• The company has sufficient capital to fund operations through Q4 2026, excluding anticipated costs for a Phase 2b study.

Negatives

• The nimacimab monotherapy arm in the Phase 2a study did not achieve the primary endpoint of weight loss compared to placebo (-1.52% vs. -0.26%).
• Preliminary pharmacokinetic analysis suggested the 200 mg subcutaneous weekly dose was suboptimal as a monotherapy.
• The company incurred a net loss of $12,509,361 for the three months ended March 31, 2026.
• Research and development expenses increased by 10% to $7,935,680 in Q1 2026.
• The company has substantial doubt about its ability to continue as a going concern beyond Q4 2026 without additional capital.
• The company received a deficiency notice from Nasdaq for failing to meet the minimum $1.00 closing bid price requirement.
• The company is facing multiple ongoing lawsuits, including a former employee wrongful termination case and securities class action and derivative lawsuits.
• Cash and cash equivalents decreased significantly from $5,882,498 at the end of 2025 to $8,149,015 at the end of Q1 2026, while short-term investments decreased from $19,854,723 to $8,959,614.

Risks

• Failure to regain compliance with Nasdaq listing requirements could lead to delisting, negatively impacting stock liquidity and market price.
• The company's ability to continue as a going concern beyond Q4 2026 is dependent on successfully raising additional capital.
• Unfavorable outcomes in ongoing litigation, particularly the Wendy Cunning lawsuit, could have a material adverse effect on financial position and operations.
• The company relies on third-party manufacturers for nimacimab production, introducing potential supply chain risks.
• There is no guarantee that higher doses of nimacimab will achieve desired efficacy or that they will not produce adverse safety and tolerability results.
• The success of nimacimab is uncertain, and competitive products or approaches could limit its commercial value.
• Macroeconomic factors such as inflation, supply chain issues, and high interest rates could adversely affect operations and financing.
• The company's ability to protect its intellectual property is crucial for its product candidates.

Future Outlook

Management estimates sufficient capital to fund operations through Q4 2026, excluding anticipated clinical and manufacturing costs for a proposed Phase 2b study. Continued operations beyond Q4 2026 depend on successfully raising additional capital through equity/debt financings or strategic relationships. The company expects to continue incurring significant losses and negative cash flows from operations.

Management Comments

• "We believe multiple factors support evaluation of nimacimab at higher doses, including the combination of preclinical toxicology safety margins and modeling; preclinical pharmacology data showing dose-dependent increases in weight loss with nimacimab monotherapy and GLP-1 combinations; and the notable safety profile in the Phase 2a study."
• "Final trial design and timing remain subject to ongoing data analysis, regulatory feedback and capital considerations."
• "Our continued operations beyond the fourth quarter of 2026 will depend on our ability to successfully raise additional capital through various potential sources, such as equity and/or debt financings, or strategic relationships."
• "If adequate funds are not available to the Company when needed it will be required to curtail or perhaps cease operations which would, in turn, further raise substantial doubt about its ability to continue as a going concern."

Industry Context

StockSavvy.ai notes that Skye Bioscience's focus on nimacimab for obesity and overweight conditions aligns with the significant market interest and investment in metabolic disease treatments. The company's strategy to combine nimacimab with existing GLP-1 therapies, like semaglutide, reflects a common approach in the industry to enhance efficacy and address patient needs, especially given the mixed results of monotherapy trials.

Comparison to Industry Standards

• The weight loss achieved by nimacimab in combination with semaglutide (-13.2%) in the Phase 2a study is comparable to or exceeds the efficacy seen in some GLP-1 monotherapy trials, such as STEP-1 (semaglutide 2.4mg) which reported an average weight loss of 10.25% at 26 weeks.
• The observed weight rebound of 17.8% in the nimacimab plus semaglutide group post-treatment is notably lower than the 37.3% rebound seen with semaglutide alone in the same analysis, suggesting a potential benefit in sustained weight management compared to current standards.
• The company's R&D expenses of $7.9 million for the quarter are within the typical range for a clinical-stage biotechnology company focused on a single lead candidate, though higher than some peers due to the advanced stage of nimacimab's trials.
• The net loss of $12.5 million for the quarter is also consistent with the financial profile of companies in this development stage, where significant investment in R&D outpaces revenue generation.

Legal Proceedings

• Wendy Cunning vs Skye Bioscience, Inc.: A former employee lawsuit alleging wrongful termination, violation of whistleblower protections, and retaliation. A new trial is scheduled for May 2026.
• Stout v. Skye Bioscience, Inc., et al.: A putative securities class action lawsuit alleging violations of Section 10(b) and Rule 10b-5 of the Exchange Act related to statements about nimacimab's efficacy and prospects.
• Domulot v. Dhillon et al. and White v. Dhillon et al.: Putative derivative lawsuits asserting claims against officers and directors for breach of fiduciary duty, unjust enrichment, and other violations related to alleged false and misleading statements about nimacimab.

Stakeholder Impact

• Shareholders: Potential delisting from Nasdaq, continued dilution from capital raises, and uncertainty regarding the company's going concern status.
• Employees: Potential impact on morale and job security due to financial challenges and ongoing litigation; stock options were repriced.
• Creditors: Potential risk if the company cannot meet its financial obligations.
• Suppliers: Potential for delayed payments or contract renegotiations if the company faces severe financial distress.

Next Steps

• Report topline data from the CBeyond Phase 2a extension study in Q3 2026.
• Report topline data from the CBeyond expansion study (Part C) in Q4 2026.
• Inform the design of a potential Phase 2b study and potential registration path for nimacimab as a combination therapy.
• Regain compliance with Nasdaq's minimum bid price requirement by September 14, 2026.
• Conduct a new trial for the Wendy Cunning lawsuit in May 2026.

Key Dates

Recommendation

While the combination therapy data for nimacimab shows promise, the failure of monotherapy, significant financial concerns including going concern doubt, and Nasdaq delisting risk warrant a cautious approach. Investors should hold and await further data and clarity on financing and Nasdaq compliance before considering a buy.

Keywords

Skye Bioscience, nimacimab, obesity, weight loss, clinical trial, Phase 2a, Nasdaq, going concern, litigation, biotechnology, GPCR, CB1 receptor, semaglutide, Form 10-Q